Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| ciliated cell | 12 studies | 26% ± 7% | |
| glutamatergic neuron | 9 studies | 38% ± 23% | |
| astrocyte | 8 studies | 28% ± 11% | |
| epithelial cell | 7 studies | 27% ± 7% | |
| oligodendrocyte | 7 studies | 24% ± 7% | |
| type I pneumocyte | 6 studies | 27% ± 9% | |
| GABAergic neuron | 4 studies | 42% ± 18% | |
| oligodendrocyte precursor cell | 4 studies | 27% ± 8% | |
| ionocyte | 3 studies | 20% ± 5% | |
| neuron | 3 studies | 27% ± 10% | |
| endothelial cell | 3 studies | 25% ± 5% | |
| club cell | 3 studies | 22% ± 5% | |
| goblet cell | 3 studies | 37% ± 28% | |
| transit amplifying cell | 3 studies | 27% ± 10% | |
| interneuron | 3 studies | 40% ± 19% | |
| kidney distal convoluted tubule epithelial cell | 3 studies | 22% ± 5% | |
| kidney loop of Henle epithelial cell | 3 studies | 23% ± 5% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 7 studies | 36% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 1691.97 | 244 / 245 | 99% | 49.68 | 498 / 502 |
| brain | 100% | 4309.74 | 2642 / 2642 | 97% | 47.38 | 685 / 705 |
| pancreas | 98% | 2076.66 | 323 / 328 | 97% | 24.67 | 172 / 178 |
| stomach | 99% | 4564.19 | 354 / 359 | 96% | 40.69 | 275 / 286 |
| lung | 99% | 1930.10 | 572 / 578 | 95% | 25.50 | 1098 / 1155 |
| intestine | 97% | 2224.98 | 940 / 966 | 97% | 46.13 | 509 / 527 |
| esophagus | 98% | 954.62 | 1411 / 1445 | 95% | 27.95 | 174 / 183 |
| kidney | 100% | 4129.09 | 89 / 89 | 91% | 30.97 | 824 / 901 |
| thymus | 100% | 6239.53 | 653 / 653 | 89% | 72.99 | 538 / 605 |
| breast | 90% | 1039.18 | 413 / 459 | 96% | 32.97 | 1072 / 1118 |
| uterus | 100% | 1099.14 | 170 / 170 | 78% | 14.56 | 356 / 459 |
| skin | 99% | 1520.10 | 1792 / 1809 | 78% | 12.84 | 366 / 472 |
| adrenal gland | 97% | 988.17 | 249 / 258 | 79% | 16.76 | 181 / 230 |
| ovary | 88% | 704.07 | 159 / 180 | 84% | 16.36 | 361 / 430 |
| bladder | 90% | 704.33 | 19 / 21 | 78% | 22.99 | 391 / 504 |
| ureter | 0% | 0 | 0 / 0 | 100% | 17.50 | 1 / 1 |
| blood vessel | 95% | 925.82 | 1270 / 1335 | 0% | 0 | 0 / 0 |
| adipose | 92% | 854.78 | 1102 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 85% | 13.69 | 68 / 80 |
| tonsil | 0% | 0 | 0 / 0 | 78% | 12.16 | 35 / 45 |
| heart | 59% | 405.30 | 510 / 861 | 0% | 0 | 0 / 0 |
| liver | 23% | 170.82 | 52 / 226 | 23% | 4.49 | 95 / 406 |
| muscle | 33% | 210.28 | 266 / 803 | 0% | 0 | 0 / 0 |
| spleen | 29% | 191.25 | 70 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 8% | 60.08 | 78 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0016020 | Cellular component | membrane |
| GO_0005515 | Molecular function | protein binding |
| Gene name | CMTM4 |
| Protein name | CKLF like MARVEL transmembrane domain containing 4 CKLF-like MARVEL transmembrane domain-containing protein 4 (Chemokine-like factor superfamily member 4) |
| Synonyms | CKLFSF4 |
| Description | FUNCTION: Acts as a backup for CMTM6 to regulate plasma membrane expression of PD-L1/CD274, an immune inhibitory ligand critical for immune tolerance to self and antitumor immunity. May protect PD-L1/CD274 from being polyubiquitinated and targeted for degradation. . |
| Accessions | ENST00000330687.8 [Q8IZR5-1] Q8IZR5 ENST00000394106.7 [Q8IZR5-2] ENST00000561680.5 J3QRP2 ENST00000563952.1 [Q8IZR5-3] |